Find policies, billing codes, payers, states, and providers
Noncontact Normothermic/Nonthermal Wound Therapy and Noncontact Fluorescence Imaging of Wounds
Customize your policy alerts
Sign up for Aetna Policy 0372 alerts
Get alerted when Policy 0372 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's coverage stance on noncontact normothermic/nonthermal wound therapies (including Warm-Up Active Wound Therapy and low-frequency noncontact ultrasound) and noncontact fluorescence imaging devices (e.g., MolecuLight) for wound care, and indicates which procedures and codes are considered experimental/investigational for Aetna members and providers.
No material clinical or coverage changes in this revision.
Coverage Criteria and Evidence Summary
Experimental and Investigational — Procedures considered experimental and investigational
The following procedures are considered experimental and investigational because effectiveness has not been established:
Exact wording from policy.
NLFU adjunctive clinical findings
Clinical findings reported in studies where noncontact low-frequency ultrasound (NLFU) was used adjunctively with standard of care (no explicit Aetna coverage criteria provided):
Examples: Chang et al. summarized LFU evidence (20–60 kHz) as promising (smaller studies) (19); Honaker prospective study (n=60) showed greater decrease in DTPI surface area and lower DTPI severity scores with NLFU plus standard care (21); Wagner-Cox retrospective review (n=44) showed significant decrease in injury size and some wounds classified as resolved after NLFU (23).
Fluorescence imaging (MolecuLight) diagnostic findings
Findings on MolecuLight fluorescence imaging utility, diagnostic performance, and effects on management reported in observational and diagnostic studies:
Examples: Hurley et al. reported sensitivity 100% and specificity 78% in outpatient setting (28); Serena pilot reported sensitivity improved from 22% (CSS alone) to 72% when FL plus CSS used and clinicians modified treatment plans in ~73% of wounds (32); Le et al. multicenter study (n=350) showed 4-fold increase in detection of >=10^4 CFU/g and FL-modified treatment plans in 69% of wounds (37); Raizman reported PPV 92.9% for cyan fluorescence predicting Pseudomonas aeruginosa (39).
Use and evidence considerations for fluorescence imaging
Consider fluorescence imaging as an adjunct to clinical assessment when detecting high bacterial burden or specific pathogens is clinically relevant:
Supported by study limitations noting 1.5 mm detection depth and inability to detect some non-porphyrin-producing bacteria (36,38,40).
Based on Le et al. multicenter results (37) and Serena pilot (32).
Supported by Raizman (39) and limitations described in other studies (36,38).
Derived from multiple chunks noting depth limits, organism detection gaps, culture limitations, and the need for longitudinal randomized trials (36,38,40,41).
The policy lists ICD-10 diagnosis code ranges and examples that are cited as indications not covered for the procedures/devices addressed. Examples include infectious disease ranges such as A00.0–A09 (intestinal infectious diseases), A20.0–A28.9 and A30.0–A49.9 (selected zoonotic and other bacterial diseases), multiple diabetes complication codes (e.g., E10.40–E10.49, E11.40–E11.49; E10.51–E10.59, E11.51–E11.59; E10.610–E10.69, E11.610–E11.69), peripheral vascular disease and atherosclerosis with ulceration or gangrene (e.g., I70.231–I70.25, I70.261–I70.269, I73.9), venous/varicose ulcer codes (e.g., I83.001–I83.029), cellulitis/abscess ranges (multiple L02.* and L03.* codes), pilonidal cyst codes (L05.01–L05.02, L05.91–L05.92), pressure ulcer codes (L89.000–L89.95), and post-procedural wound complication codes (e.g., T81.31x–T81.32x+, T81.40xA–T81.49xS, T81.89x+).
The policy identifies several device limitations and relative contraindications for fluorescence imaging. Active bleeding or highly vascularized tissue appears dark or black on fluorescence photographs and was considered a relative contraindication because it can render images unusable; irrigation was sometimes required to obtain images. Dressings containing silver also produce black images and may prevent use of the device. Additionally, the procedure requires controlled lighting (darkness) or use of an accessory DarkDrape to obtain quality images, which may limit routine clinic use.
The policy notes important limitations of fluorescence (FL) detection: the device has a maximum subsurface detection depth of approximately 1.5 mm, so organisms located deeper than this may not be detected. FL detects endogenous porphyrin-related fluorescence and therefore does not detect non-porphyrin-producing bacteria (examples cited include some species of Streptococcus, Enterococcus, and Finegoldia). Because FL cannot reliably identify all organisms or non-bacterial components, the policy recommends using FL in combination with clinical signs and, when necessary, microbiologic sampling for species-level identification or assessment of deeper infection.
Aetna considers the MolecuLight fluorescence imaging device and certain noncontact wound therapies experimental and investigational because effectiveness has not been established. Specifically, the policy names MolecuLight hand-held fluorescence imaging, noncontact, nonthermal low-frequency ultrasound therapy, and Warm-Up Active Wound Therapy (noncontact normothermic wound therapy) as procedures that are experimental/investigational and not supported as established treatments.
The document states there is currently insufficient evidence to support use of the MolecuLight device for identification and management of wounds with bacterial burden. Limitations cited include lack of longitudinal outcome data linking FL-guided decisions to improved clinical outcomes and incomplete microbiology in some studies, supporting the conclusion that the evidence is inadequate to establish the device as standard management.
Study limitations described in the policy restrict conclusions about FL-guided management. Several studies were single-visit observational trials without longitudinal follow-up to validate whether changes in treatment based on FL led to better outcomes. Microbiology confirmation was incomplete in some reports (e.g., culture results available for only a subset of wounds), and there was a low proportion of true-negative wounds in certain populations, which limits specificity and negative predictive value estimates. The policy therefore emphasizes caution in interpreting diagnostic accuracy and outcome impact from these limited studies.
Coding and Diagnosis Examples
| 0598T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity). |
| 0599T | Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure). |
| 97610 | Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day. |
| A6000 | Non-contact wound warming wound cover for use with the non-contact wound warming device and warming card. |
| E0231 | Non-contact wound warming device (temperature control unit, AC adaptor and power cord) for use with warming card and wound cover. |
| E0232 | Warming card for use with the non-contact wound warming device and non-contact wound warming cover. |
| A00.0 - A09 | Intestinal infectious diseases. |
| A20.0 - A28.9 | Certain zoonotic bacterial diseases. |
| A30.0 - A49.9 | Other bacterial diseases. |
| E10.40 - E10.49, E11.40 - E11.49 | Diabetes with neurological complications. |
| E10.51 - E10.59, E11.51 - E11.59 | Diabetes with peripheral circulatory complications. |
| E10.610 - E10.69, E11.610 - E11.69 | Diabetes with other specified complications. |
| I70.231 - I70.25 | Atherosclerosis of the lower extremities with ulceration. |
| I70.261 - I70.269 | Atherosclerosis of the lower extremities with gangrene. |
| I73.9 | Peripheral vascular disease, unspecified. |
| I74.3 | Embolism and thrombosis of arteries of the lower extremities. |
Provider Actions, Prior Authorization and Documentation
Prior authorization not expected for listed CPT/HCPCS codes
The policy identifies the listed CPT/HCPCS codes (0598T, 0599T, 97610, A6000, E0231, E0232) as procedures/devices for which effectiveness has not been established; coverage for these codes is not supported under this policy and prior authorization is unlikely to be approved.
Insufficient evidence for MolecuLight; no PA process specified here
The document states there is insufficient evidence to support use of the MolecuLight device for wound identification/management; the policy text does not specify particular prior authorization procedures or requirements for the device in these sections.
- Policy notes insufficient evidence for MolecuLight device use to identify/manage wounds with bacterial burden
- No prior authorization process or codes for MolecuLight are specified in these chunks
Policy history present; no explicit prior authorization code-level guidance
The policy history and review dates are provided, but the document does not give explicit, code-level prior authorization instructions in the cited sections.
- Last review: 06/06/2023; Effective date: 02/07/2000; Next review: 04/11/2024
- No explicit prior-authorization code-level requirements are listed in these chunks
Step therapy not established despite background discussion
The background discussion references use of these therapies after conventional wound-healing approaches or added to standard care, but the policy does not establish formal step therapy requirements.
- Policy background discusses adjunctive use following standard care or when conventional therapy fails
- No formal step therapy directives or mandated treatment sequencing are specified
NLFU studied as adjunct to standard of care (implies stepwise use)
Studies of noncontact low-frequency ultrasound (NLFU) reported its use adjunctively with standard of care rather than as a sole therapy, implying clinicians applied NLFU in a stepwise fashion alongside conventional treatments.
- Honaker (prospective study) examined NLFU plus standard of care vs standard care alone
- Wagner-Cox retrospective review reported NLFU used in treated patients alongside existing care
No step therapy directives in policy sections reviewed
The policy sections reviewed do not include step therapy directives or mandatory sequencing of therapies.
- No explicit step therapy policies or required prior treatment trials are listed in these chunks
Use listed CPT/HCPCS codes when billing; reference policy
When billing for these services, use the CPT/HCPCS codes listed in the policy (examples include 0598T, 0599T, 97610, A6000, E0231, E0232) and reference the policy; the policy also provides ICD-10 examples of diagnoses for which the codes are listed as not covered.
Include wound assessment, FL results, and microbiology in clinical documentation
Clinical documentation should include a wound assessment (clinical signs and symptoms), fluorescence imaging results if used, and microbiology swab or biopsy results when available to support clinical decisions.
- Document CSS findings and wound assessment measurements
- Record FL imaging findings and how they informed care
- Include microbiology swab/biopsy results when obtained
Document FL results and confirm with cultures when indicated
If fluorescence imaging is used, document the imaging findings and correlate them with microbiologic sampling (biopsy or curettage) when species-level identification or confirmation of bacterial load is clinically indicated.
- Record FL signals and any image-guided sampling locations
- Correlate FL findings with culture or curettage samples when needed to identify organisms (e.g., Pseudomonas confirmed by curettage in Raizman)
Denial risk for procedures/devices labeled experimental/investigational
Because the policy classifies MolecuLight fluorescence imaging, NLFU, and Warm-Up Active Wound Therapy as experimental and investigational, claims for these procedures or devices may be denied.
- Policy explicitly lists MolecuLight, noncontact LFU, and Warm-Up Active Wound Therapy as experimental/investigational
- Claims for these services/devices may not be supported and can be denied
Insufficient evidence for MolecuLight may lead to denials or coverage limits
The policy states there is insufficient evidence to support the MolecuLight device for identification and management of wounds with bacterial burden; this insufficiency may lead to prior authorization denials or coverage limitations for the device or its use.
- Policy text: 'there is currently insufficient evidence to support its use in identification and management of wounds with bacterial burden'
- Insufficient evidence may trigger denial of coverage or PA limitations
Background and study limitations — no direct authorization instructions
The cited sections provide background, study limitations, and context but do not contain direct authorization or coverage instructions; use these details to inform clinical caution and documentation but not as authorization guidance.
- Chunks describe study limitations (single-visit design, limited microbiology, detection depth) rather than authorization rules
- Clinical teams should document limitations and reasoning in the absence of explicit coverage instructions
Background and Definitions
Background: Noncontact normothermic wound therapy (also called Warm-Up Active Wound Therapy or NNWT) and other noncontact therapies are described as adjunctive wound treatments that deliver warming or energy without direct contact. The Warm-Up system consists of a domed wound cover, an infrared heating card, and a battery-powered temperature control that warms the wound surface to a set temperature while allowing exudate drainage. Noncontact low-frequency ultrasound (NLFU) and other low-frequency ultrasound approaches have been studied for biofilm dispersal, debridement, and bacterial reduction, but evidence is limited. The MolecuLight device is a handheld, noncontact fluorescence imaging system using 405 nm light to visualize bacterial fluorescence and measure wound surface area in real time; while FL can highlight regions likely to have bacterial loads ≥ 10^4 CFU/g, overall clinical effectiveness and impact on long-term healing remain unproven according to the policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.